Should I Buy BJDX? BJDX 2026 Analysis

Should You Buy Bluejay Diagnostics Inc (BJDX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

3.820

1 Day change

17.53%

52 Week Range

40.800

Analysis Updated At

2026/01/28

BJDX is not a good buy right now for a beginner, long-term investor with $50,000–$100,000 who doesn’t want to wait for better entry points. The stock is a sub-$1 microcap with no revenue, ongoing losses, and deteriorating EPS, while the recent +10% pop is running into nearby resistance—this looks more like a short-term bounce than a durable long-term setup. If you already own it, selling into this strength is the more favorable decision than adding.

Technical Analysis

Price/Trend: Strong single-day upside (+10.33%) in the regular session, but the broader signal set does not confirm a sustained uptrend. Momentum: MACD histogram is positive (0.0431) and expanding, which is bullish near-term. RSI: RSI(6) at 68.655 is near the upper end of neutral (approaching overbought), suggesting upside may be limited without consolidation. Moving Averages: Converging moving averages implies lack of a clean trend and higher whipsaw risk. Levels: Pivot support ~0.80. Immediate resistance at R1 ~0.934, then R2 ~1.017. With price ~0.865, the stock is closer to resistance than support, which is not ideal for an impatient entry. Pattern-based forward view (provided): modest negative bias over 1 week (-0.07%) and 1 month (-0.03%), offering no strong tailwind. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Positive Catalysts

Technical momentum is currently positive (MACD expanding) and price is showing a short-term bounce. No reported insider or hedge fund selling trends in the provided data.

Neutral/Negative Catalysts

No recent news catalysts provided to justify a sustained re-rating. The stock is trading below $1 and is prone to sharp reversals. Near-term technical setup is closer to resistance (0.934) than support (0.80), making the risk/reward unattractive for a fresh long-term entry. No congress trading data and no notable institutional/insider trend signals were provided to support conviction.

Financial Performance

Latest quarter: 2025/Q3. Revenue was 0 (0.00% YoY), indicating no commercial traction in the reported period. Net income improved to -$1,597,632 (+7.81% YoY), but the company remains meaningfully unprofitable. EPS dropped to -1.01 (-86.97% YoY), a significant deterioration in per-share performance, which is a negative long-term signal for equity holders.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target data was provided, suggesting limited or no recent Wall Street coverage in this dataset. With no visible upward revisions or supportive target changes, there’s no analyst-driven confirmation of a long-term upside case here.

Analyst Rating

Wall Street analysts forecast BJDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BJDX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold